Cleared Traditional

K822666 - ANTISERUM TO HUMAN KAPPA

K822666 is the FDA 510(k) clearance for ANTISERUM TO HUMAN KAPPA by Amico Lab, Inc.. It is a Class 2 Microbiology device (product code DFH) cleared through the Traditional 510(k) pathway after a 75-day FDA review.

K822666 · Amico Lab, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1982
Decision
75d
Days
Class 2
Risk

K822666 is an FDA 510(k) clearance for the ANTISERUM TO HUMAN KAPPA. Classified as Kappa, Antigen, Antiserum, Control (product code DFH), Class II - Special Controls.

Submitted by Amico Lab, Inc. (Mchenry, US). The FDA issued a Cleared decision on November 17, 1982 after a review of 75 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.5550 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Amico Lab, Inc. devices

Submission Details

510(k) Number K822666 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 03, 1982
Decision Date November 17, 1982
Days to Decision 75 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
27d faster than avg
Panel avg: 102d · This submission: 75d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DFH Kappa, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5550
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - DFH Kappa, Antigen, Antiserum, Control

All 53
Devices cleared under the same product code (DFH) and FDA review panel - the closest regulatory comparables to K822666.
QUANTIMETRIC PLUS KAPPA REAGENT KIT
K855008 · Kallestad Laboratories, Inc. · Feb 1986
TISSUE-TEK IMMUNOHISTOLOGY KIT LYSOZZM
K842470 · Miles Laboratories, Inc. · Aug 1984
AMER. HISTO-ID SYS PRIMARY KIT
K842326 · Bartels Immunodiagnostic Supplies, Inc. · Aug 1984
ANTISERUM TO HUMAN LAMBDA
K822667 · Amico Lab, Inc. · Nov 1982
ANTISERUM TO HUMAN IGA
K822668 · Amico Lab, Inc. · Nov 1982
ANTISERUM TO HUMAN IGG
K822669 · Amico Lab, Inc. · Nov 1982